Flagyl ER
Flagyl ER Price range: $ 44,00 through $ 139,00
Back to products
Flibanserin
Flibanserin Price range: $ 48,00 through $ 264,00

Flexeril

Price range: $ 57,00 through $ 648,00

Flexeril is a highly effective muscle relaxant specifically designed to alleviate discomfort associated with acute musculoskeletal conditions. It works by blocking nerve impulses or pain sensations sent to the brain, providing targeted relief from localized muscle spasms. This medication helps to significantly reduce stiffness and pain, allowing for improved physical function and ease of movement. It is typically used for short-term recovery periods to complement rest and physical therapy for the optimal healing of muscle injuries. Flexeril remains a trusted choice for individuals seeking to restore comfort and regain flexibility after a sudden muscle strain.

Active substance: Cyclobenzaprine
SKU: Flexeril Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Cyclobenzaprine hydrochloride, formerly marketed under the brand name Flexeril, belongs to the class of central nervous system muscle relaxants. It is prescribed by healthcare providers as an adjunct to rest and physical therapy for the symptomatic relief of muscle spasms associated with acute, painful musculoskeletal conditions.

This prescription medication is intended only for short-term clinical use, typically up to two to three weeks, as adequate evidence of effectiveness for more prolonged use is not available. As an FDA-regulated prescription drug in the United States, Flexeril requires a valid evaluation and order from a licensed healthcare provider before dispensing.

Property Details
Drug name Flexeril
Active ingredient Cyclobenzaprine hydrochloride
Therapeutic class Central skeletal muscle relaxant
Dosage form Oral tablet
Route of administration Oral
Prescription status Prescription (Rx) only

How the drug works

Cyclobenzaprine hydrochloride relieves skeletal muscle spasms of local origin without interfering with muscle function. Pharmacological studies indicate that cyclobenzaprine acts primarily within the central nervous system at the brainstem level, as opposed to the spinal cord level, although an action on the spinal cord may contribute to its overall skeletal muscle relaxant activity.

Evidence demonstrates that cyclobenzaprine reduces tonic somatic motor activity by influencing both gamma and alpha motor systems. Structurally, cyclobenzaprine is closely related to tricyclic antidepressants, which accounts for its characteristic pharmacological profile, including central anticholinergic properties and potential interactions with central neurotransmitter systems. It possesses no direct action on the neuromuscular junction or on peripheral skeletal muscle tissue.

Main uses

Flexeril is indicated as an adjunct to rest and physical therapy for the relief of muscle spasm associated with acute, painful musculoskeletal conditions. Clinical improvement is manifested by relief of muscle spasms and associated signs and symptoms, including pain, tenderness, limitation of motion, and restriction in activities of daily living.

It should be emphasized that Flexeril is indicated only for short-term therapy, usually up to two to three weeks. Musculoskeletal spasms of short duration rarely persist beyond this timeframe, and long-term efficacy data are not established. Flexeril has not been shown to be effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.

Dosing schedule

The standard adult dosage of cyclobenzaprine hydrochloride is 5 mg or 10 mg administered orally three times daily. Depending on individual patient response and clinical objective, a physician may initiate therapy at 5 mg three times daily and titrate to 10 mg three times daily if necessary. The maximum recommended daily dose is 30 mg.

The use of Flexeril for periods longer than two to three weeks is not recommended. For patients with mild hepatic impairment, dosing should be initiated with caution, typically starting at a 5 mg dose and titrating slowly. For elderly individuals, initial dosing should likewise begin at the lowest therapeutic level due to decreased clearance and increased sensitivity to central nervous system adverse effects.

How it’s absorbed and eliminated

Following oral administration, cyclobenzaprine hydrochloride is well absorbed from the gastrointestinal tract, reaching mean peak plasma concentrations within 3 to 8 hours. The drug exhibits significant structural similarity to tricyclic compounds and undergoes extensive first-pass hepatic metabolism. It is bound extensively to human plasma proteins, approximately 93%.

Cyclobenzaprine is heavily metabolized via hepatic cytochrome P450 enzymes, primarily CYP3A4, CYP1A2, and to a lesser extent CYP2D6. Elimination occurs slowly, with a mean elimination half-life ranging from 8 to 37 hours (average approximately 18 hours). Excretion occurs predominantly via the kidneys as inactive glucuronide metabolites, with a smaller proportion eliminated in the feces. Accumulation of the drug may occur in patients with compromised liver function.

Compatibility with other medicines

Flexeril exhibits critical interactions with several drug classes. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated. Hyperpyretic crisis, severe convulsions, and death have occurred in patients receiving cyclobenzaprine or structurally similar tricyclic antidepressants concurrently with MAOIs. At least 14 days must elapse after discontinuing an MAOI before initiating cyclobenzaprine therapy.

Flexeril may enhance the sedative effects of alcohol, barbiturates, benzodiazepines, and other central nervous system depressants. Concomitant use with serotonergic drugs–such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, or tramadol–increases the risk of serotonin syndrome, a potentially life-threatening condition. Additionally, combined use with anticholinergic agents may produce additive anticholinergic adverse effects, such as severe dry mouth, urinary retention, or constipation.

First days of treatment

During the initial days of treatment with Flexeril, patients frequently experience marked sedation or drowsiness. This central nervous system effect usually manifests within the first few doses as therapeutic serum levels are established. Patients should observe how the medication affects them before attempting tasks that require full mental alertness.

Dry mouth and lightheadedness are also common during the early phase of therapy. These physiological responses typically align with the onset of peak plasma concentrations. If severe sedation or functional impairment occurs during the first few days, consultation with the prescribing clinician is recommended to evaluate whether a dose adjustment is warranted.

Adverse reactions

The most common adverse reactions reported during clinical trials of cyclobenzaprine hydrochloride involve the central nervous system and cholinergic systems. Drowsiness (somnolence) occurs in approximately 29% to 38% of patients receiving 10 mg three times daily. Dry mouth (xerostomia) is reported in 21% to 32% of patients, and dizziness occurs in 1% to 11%.

Less common adverse reactions, occurring in 1% to 3% of patients, include fatigue, headache, confusion, nausea, constipation, dyspepsia, unpleasant taste, and blurred vision. Post-marketing surveillance has identified rare but clinically significant adverse events, including tachycardia, cardiac arrhythmias, palpitation, hypotension, syncope, cholestatic jaundice, hypersensitivity reactions (anaphylaxis, angioedema, urticaria), and psychomotor agitation.

Red Flag Symptom Immediate Clinical Significance
Swelling of face, lips, tongue, or throat Possible severe acute hypersensitivity reaction (angioedema/anaphylaxis).
Chest pain, rapid or irregular heartbeat Potential cardiac arrhythmia or cardiovascular toxicity.
Agitation, hallucinations, hyperreflexia, high fever Signs indicative of potential Serotonin Syndrome.
Difficulty breathing or swallowing Emergency airway compromise requiring urgent medical intervention.
Urinary retention or inability to urinate Severe anticholinergic urinary tract obstruction.

Important precautions

Flexeril is contraindicated in patients with a history of hypersensitivity to cyclobenzaprine hydrochloride or any component of the formulation. It is contraindicated during the acute recovery phase following myocardial infarction, in patients with cardiac conduction disturbances, heart block, heart failure, or established cardiac arrhythmias. Flexeril is also contraindicated in patients with hyperthyroidism due to heightened risks of tachycardia and cardiovascular complications.

Because of its atropine-like action, cyclobenzaprine should be used with extreme caution in patients with a history of urinary retention, angle-closure glaucoma, or increased intraocular pressure. Healthcare providers should closely evaluate patients with mild hepatic impairment before prescribing, as plasma clearance is reduced in this population.

What to avoid while taking it

Patients taking Flexeril must avoid the consumption of alcoholic beverages. Alcohol potentiates the central nervous system depressant effects of cyclobenzaprine, markedly increasing sedation, motor impairment, and cognitive slowing. Similarly, non-prescribed sedatives, tranquilizers, or sleep aids should not be combined with Flexeril without explicit medical guidance.

Activities requiring mental alertness and precise motor coordination–such as driving a motor vehicle, operating heavy machinery, or working at dangerous heights–should be avoided until the patient’s individual response to the medication has been fully determined. Flexeril tablets may be taken with or without food, as food co-administration does not significantly alter overall bioavailability.

Special populations

In pregnant women, adequate and well-controlled clinical studies have not been conducted. Animal reproduction studies have not demonstrated fetal risk, but because animal data are not always predictive of human response, cyclobenzaprine should be used during pregnancy only if clearly needed. It is not known whether cyclobenzaprine is excreted in human milk; caution should be exercised when administered to a nursing mother.

Safety and effectiveness of Flexeril in pediatric patients below 15 years of age have not been established. In elderly populations (65 years of age and older), plasma concentrations of cyclobenzaprine are significantly elevated, and the elimination half-life is prolonged. Elderly patients are at increased risk for central nervous system adverse events, confusion, hallucination, and falls. Consequently, dose selection for an elderly patient should be cautious, starting at the lower end of the dosing range.

If you skip a dose

If a scheduled dose of Flexeril is missed, it should be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular dosing schedule resumed.

Patients must not double the dose or take extra tablets to compensate for a missed dose. Overdosage of cyclobenzaprine can cause serious central nervous system and cardiovascular toxicity, including confusion, convulsions, severe hypothermia, dilated pupils, and life-threatening arrhythmias.

Common questions

How quickly does Flexeril begin to relieve muscle spasms?

Initial symptomatic relief from muscle spasms and associated discomfort usually begins within 1 to 2 hours following oral administration. Peak plasma concentrations are reached within 3 to 8 hours. Full therapeutic response depends on maintaining consistent plasma levels as directed by the prescribing physician, alongside recommended physical therapy and rest.

Why is Flexeril restricted to short-term use of 2 to 3 weeks?

Flexeril is approved strictly for short-term management because clinical trials have only established safety and efficacy for up to three weeks. Furthermore, acute musculoskeletal spasms generally resolve within this timeframe. Prolonged use increases the risk of anticholinergic side effects and cumulative central nervous system toxicity without proven clinical benefit.

Can Flexeril be taken alongside over-the-counter pain relievers?

Flexeril is frequently prescribed as part of a comprehensive regimen that may include nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or acetaminophen, provided there are no contraindications. However, patients should consult their pharmacist or prescriber to confirm that concurrent pain medications do not contain sedating ingredients or antihistamines that could compound central nervous system depression.

Is it safe to drive while taking Flexeril?

Driving or operating machinery is not recommended when initiating treatment with Flexeril. Drowsiness and impaired reaction times are among the most common adverse effects of cyclobenzaprine. Patients should refrain from performing hazardous tasks until they have established how the medication impacts their central nervous system alertness.

What should be done if dry mouth becomes troublesome during treatment?

Dry mouth is a recognized anticholinergic effect of cyclobenzaprine. Patients experiencing xerostomia can manage mild symptoms by maintaining adequate hydration, sucking on sugarless hard candies, or using oral moisturizing gels. If dry mouth is severe, persistent, or accompanied by difficulty swallowing, the prescribing healthcare provider should be consulted.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

15mg

Package

20 pills

,

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία